Dipeptidyl peptidase-IV inhibitory peptides derived from salmon milt and their effects on postprandial blood glucose level

Yoshinori Takahashi,Tatsuya Konishi,Akira Kamata

doi:10.1007/s12562-021-01530-9

Abstract

The hydrolysate of Oncorhynchus keta (chum salmon) milt was found to exhibit strong inhibitory activity against dipeptidyl peptidase-IV (DPP-IV), and the hypoglycaemic effect of these salmon milt peptides (SMPs) was confirmed using oral starch tolerance tests in Sprague–Dawley rats. Specifically, the oral administration of SMPs at a dose of 300 mg/kg body weight for 1 week resulted in a significant decrease in the blood glucose level of the rats 60 min after starch consumption compared with the control. The bioassay-guided separation of SMPs, using a combination of column chromatographic techniques, led to the identification of 12 active di-, tri- and tetrapeptides, including four novel DPP-IV inhibitory peptides, namely Phe-Pro-Val-Gly, Leu-Pro-Val-Leu, Val-Pro-Phe-Pro and Ile-Pro-Leu. Among these 12 peptides, Ile-Pro contributed the most (1.3%) to the total DPP-IV inhibitory activity of SMPs. Therefore, SMPs may have the potential to be used as a suppressor of postprandial hyperglycaemia and to be considered a promising functional food material for the prevention of type II diabetes.

Highlights

Diabetes, which is caused by a lack of insulin action, is a metabolic disease that is characterised by chronic hyperglycaemia
Several compounds with the ability to inhibit dipeptidyl peptidase IV (DPP-IV) have been obtained via chemical synthesis, these are associated with numerous safety issues and adverse side effects
Protease P “Amano” 3SD, which was derived from Aspergillus melleus, exhibited the strongest DPP-IV inhibitory activity (59.2% at a concentration of 300 μg/mL), and its yield from wet salmon milt was 4.6% w/w

Summary

Introduction

Diabetes, which is caused by a lack of insulin action, is a metabolic disease that is characterised by chronic hyperglycaemia. Blood glucose control can suppress the onset of diabetes, and hinder the development of related complications, such as retinopathy, nephropathy, neuropathy, myocardial infarction and cerebral infarction. It can improve the quality of life and life expectancy of patients. Dipeptidyl peptidase IV (DPP-IV) inhibitors, such as sitagliptin and alogliptin, have. Several compounds with the ability to inhibit DPP-IV have been obtained via chemical synthesis, these are associated with numerous safety issues and adverse side effects. Reports of DPP-IV inhibitors derived from natural products include peptides derived from whey

Methods

Results

Conclusion